Clinical studies in NSCLC suggest that overall survival (OS) benefits from single-agent anti–PD-(L)1 mainly in patients with ≥50% PD-L1 expression, while patients with negative/low PD-L1 expression only occasionally benefit (20, 21). This evidence concerns the gene CD274 and non-small cell lung carcinoma.